These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24164039)

  • 21. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222.
    Tew CJ; Lane DA; Thompson E; Ireland H; Curtis JR
    Br J Haematol; 1988 Nov; 70(3):335-40. PubMed ID: 2849981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure.
    Stratta P; Karvela E; Canavese C; Quaglia M; Lazzarich E; Fenoglio R; Pergolini P; Bellomo G; Cena T; Magnani C
    Curr Med Chem; 2009; 16(23):3028-40. PubMed ID: 19689280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Qualitative and quantitative analysis of heparin and low molecular weight heparins using size exclusion chromatography with multiple angle laser scattering/refractive index and inductively coupled plasma/mass spectrometry detectors.
    Ouyang Y; Zeng Y; Yi L; Tang H; Li D; Linhardt RJ; Zhang Z
    J Chromatogr A; 2017 Nov; 1522():56-61. PubMed ID: 28958760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
    Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.
    Agnelli G; Iorio A; Renga C; Boschetti E; Nenci GG; Ofosu FA; Hirsh J
    Circulation; 1995 Nov; 92(10):2819-24. PubMed ID: 7586247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
    Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
    Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit.
    White H; Sosnowski K; Bird R; Jones M; Solano C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):304-10. PubMed ID: 22473047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions.
    Barrowcliffe TW; Le Shirley Y
    Thromb Haemost; 1989 Nov; 62(3):950-4. PubMed ID: 2556814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
    Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
    Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring of low-molecular-weight heparins in cardiovascular disease.
    Abbate R; Gori AM; Farsi A; Attanasio M; Pepe G
    Am J Cardiol; 1998 Sep; 82(5B):33L-36L. PubMed ID: 9737479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study.
    Coene KLM; Dekker MJE; Kerskes MCHM; Hengst M; Schonck MJM; Konings CJAM; Scharnhorst V
    Nephron; 2017; 137(3):205-211. PubMed ID: 28817831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New data on the pharmacology of heparin and low molecular weight heparins.
    Samama MM; Bara L; Gouin-Thibault I
    Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.